Zofran (ondansetron) MDL Hearing Scheduled for October

Oral arguments have been scheduled for October 1, 2015 over whether Zofran (ondansetron) claims will be centralized before one judge—a mechanism courts use called a multi-district litigation, or MDL. The 36 cases pending before more than 20 courts nationwide similarly allege that GlaxoSmithKline’s anti-nausea drug Zofran (ondansetron) caused a myriad of birth defects when used during pregnancy, namely congenital heart defects and cleft palate. Attorneys at Grant & Eisenhofer have been at the forefront of the litigation, and filed the first cases on behalf of families whose children have suffered from GSK’s alleged “off label” marketing, as the U.S. Food and Drug Administration never approved Zofran (ondansetron) for use in expectant mothers. As more cases are filed by families seeking justice against GSK, the MDL could balloon to include several hundred more cases.

Real Time Analytics